Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel Free BBOT Stock Alerts

BridgeBio Oncology Therapeutics (BBOT) Financials

BridgeBio Oncology Therapeutics logo
$8.51 +0.43 (+5.32%)
Closing price 04:00 PM Eastern
Extended Trading
$8.52 +0.01 (+0.06%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for BridgeBio Oncology Therapeutics

Annual Income Statements for BridgeBio Oncology Therapeutics

This table shows BridgeBio Oncology Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -0.04 -74 -134
Consolidated Net Income / (Loss)		 -0.04 -74 -134
Net Income / (Loss) Continuing Operations		 -0.04 -74 -134
Total Pre-Tax Income 		-0.04 -74 -134
Total Operating Income		 -0.04 -81 -146
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Operating Revenue		 - 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 0.04 81 146
Selling, General & Admin Expense		 0.04 7.76 25
Research & Development Expense		 - 73 121
Total Other Income / (Expense), net		 0.00 6.59 12
Interest & Investment Income		 0.00 6.38 11
Other Income / (Expense), net		 0.00 0.21 0.43
Basic Earnings per Share		 $0.00 ($5,756.41) ($4.30)
Weighted Average Basic Shares Outstanding		 0.00 12.90K 31.14M
Diluted Earnings per Share		 $0.00 ($5,756.41) ($4.30)
Weighted Average Diluted Shares Outstanding		 0.00 12.90K 31.14M
Weighted Average Basic & Diluted Shares Outstanding		 - 23.51M 80.03M

Quarterly Income Statements for BridgeBio Oncology Therapeutics

This table shows BridgeBio Oncology Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 0.00 0.00 -0.04 1.14 4.65 -17 2.07 -0.43 2.99 -45 -92
Consolidated Net Income / (Loss)		 0.00 0.00 -0.04 1.14 4.65 -17 1.88 -0.43 2.99 -45 -92
Net Income / (Loss) Continuing Operations		 0.00 0.00 -0.04 1.14 4.65 -17 2.07 -0.43 2.99 -45 -92
Total Pre-Tax Income 		0.00 0.00 -0.04 1.14 4.65 -17 2.07 -0.43 2.99 -45 -92
Total Operating Income		 0.00 0.00 -0.04 -0.07 -0.15 -20 -0.22 -2.42 -1.12 -49 -93
Total Gross Profit		 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 -0.00
Total Revenue		 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 -0.00
Operating Revenue		 - - - 0.00 0.00 0.00 - 0.00 0.00 0.00 -0.00
Total Operating Expenses		 0.00 0.00 0.04 0.07 0.15 20 0.18 2.42 1.12 49 93
Selling, General & Admin Expense		 0.00 0.00 - 0.07 0.15 1.78 - 2.42 1.12 14 6.95
Total Other Income / (Expense), net		 0.00 0.00 - 1.17 4.81 2.34 2.37 1.93 4.12 4.42 1.30
Interest & Investment Income		 0.00 0.00 - 1.21 2.44 2.47 2.25 1.99 2.07 3.44 3.83
Basic Earnings per Share		 $0.00 $0.00 - $0.16 $0.18 ($1,562.18) - ($0.04) $0.08 ($1.03) ($3.31)
Weighted Average Basic Shares Outstanding		 4M 0.00 0.00 14.19M 23.51M 11.09K 21.16M 23.51M 23.51M 43.49M 31.14M
Diluted Earnings per Share		 $0.00 $0.00 - $0.16 $0.18 ($1,562.18) - ($0.04) $0.08 ($1.03) ($3.31)
Weighted Average Diluted Shares Outstanding		 4M 0.00 0.00 14.47M 23.51M 11.09K 21.24M 23.51M 23.51M 43.49M 31.14M
Weighted Average Basic & Diluted Shares Outstanding		 - - 0.00 23M 23.51M 23.51M 23.51M 23.51M 23.51M 79.99M 80.03M

Annual Cash Flow Statements for BridgeBio Oncology Therapeutics

This table details how cash moves in and out of BridgeBio Oncology Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.00 31 343
Net Cash From Operating Activities		 0.00 -55 -114
Net Cash From Continuing Operating Activities		 0.00 -55 -114
Net Income / (Loss) Continuing Operations		 -0.04 -74 -134
Consolidated Net Income / (Loss)		 -0.04 -74 -134
Depreciation Expense		 - 0.21 0.28
Amortization Expense		 - -1.54 -0.93
Non-Cash Adjustments To Reconcile Net Income		 0.03 4.43 14
Changes in Operating Assets and Liabilities, net		 0.02 16 7.16
Net Cash From Investing Activities		 0.00 -121 73
Net Cash From Continuing Investing Activities		 0.00 -121 73
Purchase of Property, Plant & Equipment		 - -0.05 -0.61
Purchase of Investments		 - -152 -84
Sale and/or Maturity of Investments		 - 32 158
Net Cash From Financing Activities		 0.00 206 383
Net Cash From Continuing Financing Activities		 0.00 206 383
Repurchase of Common Equity		 - 0.00 -12
Issuance of Preferred Equity		 - 205 22
Issuance of Common Equity		 0.00 0.00 373
Other Financing Activities, net		 0.00 1.11 0.05

Quarterly Cash Flow Statements for BridgeBio Oncology Therapeutics

This table details how cash moves in and out of BridgeBio Oncology Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 - - - 1.84 -0.03 18 -0.09 -0.73 -0.30 379 -35
Net Cash From Operating Activities		 - - - -0.62 -0.03 -39 -0.09 -0.73 -0.30 -71 -42
Net Cash From Continuing Operating Activities		 - - - -0.62 -0.03 -39 -0.09 -0.73 -0.30 -71 -42
Net Income / (Loss) Continuing Operations		 - - -0.04 1.10 2.21 -58 1.95 -0.49 0.92 -96 -39
Consolidated Net Income / (Loss)		 - - -0.04 1.10 2.21 -58 1.95 -0.49 0.92 -96 -39
Depreciation Expense		 - - - - - - - - - - 0.08
Amortization Expense		 - - - - - - - - - - -1.15
Non-Cash Adjustments To Reconcile Net Income		 - - 0.03 -1.25 -2.36 6.86 -2.17 -1.93 -2.04 14 3.39
Changes in Operating Assets and Liabilities, net		 - - 0.02 -0.47 0.12 12 0.13 1.68 0.82 10 -5.76
Net Cash From Investing Activities		 - - - -184 - 38 - 0.00 - 66 7.77
Net Cash From Continuing Investing Activities		 - - - -184 - 38 - 0.00 - 66 7.77
Purchase of Property, Plant & Equipment		 - - - - - - - - - - -0.07
Purchase of Investments		 - - - - - - - - - - -21
Sale and/or Maturity of Investments		 - - - - - - - - - - 29
Net Cash From Financing Activities		 - - - 186 - 20 - 0.00 - 384 -0.59
Net Cash From Continuing Financing Activities		 - - - 186 - 20 - 0.00 - 384 -0.59
Issuance of Preferred Equity		 - - - - - - - - - - 22
Other Financing Activities, net		 - - - - - - - - - - 12

Annual Balance Sheets for BridgeBio Oncology Therapeutics

This table presents BridgeBio Oncology Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.33 164 448
Total Current Assets		 0.00 159 432
Cash & Equivalents		 0.00 31 374
Short-Term Investments		 - 125 52
Accounts Receivable		 - 0.08 0.39
Prepaid Expenses		 0.00 2.98 6.55
Plant, Property, & Equipment, net		 0.00 0.49 0.96
Total Noncurrent Assets		 0.33 5.12 15
Other Noncurrent Operating Assets		 0.33 5.12 15
Total Liabilities & Shareholders' Equity		 0.33 164 448
Total Liabilities		 0.40 20 37
Total Current Liabilities		 0.40 20 35
Short-Term Debt		 0.07 0.48 0.53
Accounts Payable		 - 3.07 1.37
Accrued Expenses		 0.33 9.10 27
Current Employee Benefit Liabilities		 - 3.82 5.75
Other Current Liabilities		 0.00 3.11 0.52
Total Noncurrent Liabilities		 0.00 0.00 2.24
Other Noncurrent Operating Liabilities		 0.00 0.00 2.24
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -0.06 145 411
Total Preferred & Common Equity		 -0.06 -179 411
Preferred Stock		 0.00 323 0.00
Total Common Equity		 -0.06 -179 411
Common Stock		 0.03 44 768
Retained Earnings		 -0.09 -223 -357
Accumulated Other Comprehensive Income / (Loss)		 - 0.35 0.02

Quarterly Balance Sheets for BridgeBio Oncology Therapeutics

This table presents BridgeBio Oncology Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 188 190 192 196 197 485
Total Current Assets		 2.11 2.08 2.04 1.24 0.88 476
Cash & Equivalents		 1.84 1.81 1.79 0.96 0.66 409
Short-Term Investments		 - - - - - 60
Prepaid Expenses		 0.27 0.01 0.25 0.21 0.21 7.50
Other Current Assets		 - - - - - 0.23
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.83
Total Noncurrent Assets		 185 188 190 194 197 7.96
Other Noncurrent Operating Assets		 185 188 190 194 197 7.96
Total Liabilities & Shareholders' Equity		 188 190 192 196 197 485
Total Liabilities		 5.54 5.60 5.65 7.39 8.15 38
Total Current Liabilities		 0.02 0.08 0.13 1.87 2.63 36
Short-Term Debt		 0.00 0.00 0.00 0.09 0.11 0.69
Accounts Payable		 - - - - 2.52 3.65
Accrued Expenses		 0.02 0.08 0.13 1.78 - 26
Current Employee Benefit Liabilities		 - - - - - 4.49
Other Current Liabilities		 - - - - - 0.51
Total Noncurrent Liabilities		 5.52 5.52 5.52 5.52 5.52 2.38
Other Noncurrent Operating Liabilities		 - 5.52 5.52 5.52 5.52 2.38
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -3.22 -3.37 -3.52 -6.15 -7.27 447
Total Preferred & Common Equity		 -3.22 -3.37 -3.52 -6.15 -7.27 447
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -3.22 -3.37 -3.52 -6.15 -7.27 447
Common Stock		 0.00 0.00 0.00 0.00 0.00 764
Retained Earnings		 -3.22 -3.37 -3.52 -6.15 -7.27 -318
Accumulated Other Comprehensive Income / (Loss)		 - - - - - 0.04

Annual Metrics And Ratios for BridgeBio Oncology Therapeutics

This table displays calculated financial ratios and metrics derived from BridgeBio Oncology Therapeutics' official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 - 79,988,687.00
DEI Adjusted Shares Outstanding		 0.00 - 79,988,687.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 - -1.68
Growth Metrics		 - - -
Profitability Metrics		 - - -
Net Operating Profit after Tax (NOPAT)		 -0.03 -0.58 -102
Return On Investment Capital (ROIC_SIMPLE)		 -447.20% 15.66% -24.80%
Earnings before Interest and Taxes (EBIT)		 -0.04 -0.58 -145
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.04 -0.58 -146
Valuation Ratios		 - - -
Leverage & Solvency		 - - -
Liquidity Ratios		 - - -
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -188 -99
Efficiency Ratios		 - - -
Capital & Investment Metrics		 - - -
Invested Capital		 0.01 187 -14
Increase / (Decrease) in Invested Capital		 0.00 187 -3.40
Book Value per Share		 $0.00 ($0.18) $5.14
Tangible Book Value per Share		 $0.00 ($0.18) $5.14
Total Capital		 0.01 189 412
Total Debt		 0.07 0.00 0.53
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 0.07 -1.70 -425
Capital Expenditures (CapEx)		 0.00 0.00 0.61
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.33 0.06 -28
Debt-free Net Working Capital (DFNWC)		 -0.33 1.76 398
Net Working Capital (NWC)		 -0.40 1.76 397
Net Nonoperating Expense (NNE)		 0.01 -8.18 32
Net Nonoperating Obligations (NNO)		 0.07 -1.72 -425
Total Depreciation and Amortization (D&A)		 0.00 0.00 -0.65
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 $0.72 ($4.30)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 21.16M 31.14M
Adjusted Diluted Earnings per Share		 $0.00 $0.72 ($4.30)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 21.24M 31.14M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 23.51M 80.03M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.03 -0.41 -102
Debt Service Ratios		 - - -
Payout Ratios		 - - -

Quarterly Metrics And Ratios for BridgeBio Oncology Therapeutics

This table displays calculated financial ratios and metrics derived from BridgeBio Oncology Therapeutics' official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
DEI Shares Outstanding		 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 79,988,687.00
DEI Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 79,988,687.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 -1.15
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 0.00 0.00 -0.03 -0.07 -0.15 -14 -0.22 -1.69 -1.12 -34 -65
Return On Investment Capital (ROIC_SIMPLE)		 - - -447.20% 2.07% 4.52% 391.35% 5.85% 27.95% 15.66% -7.70% -15.83%
Earnings before Interest and Taxes (EBIT)		 0.00 0.00 -0.04 -0.07 2.21 -20 -0.22 -2.42 0.92 -48 -93
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 0.00 0.00 -0.04 -0.07 2.21 -20 -0.22 -2.42 0.92 -48 -94
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 -180 -182 -199 -187 -8.96 -7.74 171 -62
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 0.00 0.01 180 182 185 187 187 189 -21 -14
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 180 182 185 187 7.27 6.62 -206 -3.40
Book Value per Share		 $0.00 $0.00 $0.00 ($0.23) ($0.14) ($317.19) ($0.18) ($0.26) ($0.31) $10.27 $5.14
Tangible Book Value per Share		 $0.00 $0.00 $0.00 ($0.23) ($0.14) ($317.19) ($0.18) ($0.26) ($0.31) $10.27 $5.14
Total Capital		 0.00 0.00 0.01 182 184 187 189 188 189 447 412
Total Debt		 0.00 0.00 0.07 0.00 0.00 0.00 0.00 0.09 0.11 0.69 0.53
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 0.00 0.07 -1.84 -1.81 -1.79 -1.70 -0.88 -0.56 -468 -425
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 -0.33 0.24 0.18 0.13 0.06 -1.51 -2.31 -27 -28
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 -0.33 2.09 2.00 1.92 1.76 -0.54 -1.65 441 398
Net Working Capital (NWC)		 0.00 0.00 -0.40 2.09 2.00 1.92 1.76 -0.63 -1.75 440 397
Net Nonoperating Expense (NNE)		 0.00 0.00 0.01 -1.21 -4.81 3.56 -2.09 -1.26 -4.12 10 27
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.07 -1.84 -2.21 -1.87 -1.72 -0.88 -0.56 -468 -425
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.07
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.09 $0.20 $0.00 ($0.04) $0.08 ($1.03) ($3.31)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 14.19M 23.51M 23.51M 21.16M 23.51M 23.51M 43.49M 31.14M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.09 $0.20 $0.00 ($0.04) $0.08 ($1.03) ($3.31)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 14.47M 23.51M 23.51M 21.24M 23.51M 23.51M 43.49M 31.14M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 23M 23.51M 23.51M 23.51M 23.51M 23.51M 79.99M 80.03M
Normalized Net Operating Profit after Tax (NOPAT)		 0.00 0.00 -0.03 -0.05 -0.11 -14 -0.15 -1.69 -0.79 -34 -65
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Financials Breakdown Chart

Key Financial Trends

Here is a concise, investor-focused snapshot of BBOT (BridgeBio Oncology Therapeutics) based on the latest four years of quarterly financials provided. The company shows minimal operating revenue and ongoing losses, with a notable cash runway added in 2025 via a large equity raise. Profitability remains distant, and cash flow is highly dependent on financing activity.

  • In Q3 2025, the company raised about $373,457,000 through issuance of common equity, supported by a net financing inflow of roughly $383,988,000 (and the same amount in net financing activities), significantly boosting liquidity.
  • As of Q3 2025, BBOT carried a strong cash position: $408,741,000 in cash & equivalents, with total current assets of around $476,010,000, indicating substantial liquidity to fund near-term activities.
  • Revenue remains minimal across 2024–2025. For example, 2025 Q2 revenue was $1,159 and Q1 2025 revenue was $2,445, with little to no operating profit tied to product sales (typical for an early-stage biotech SPAC scenario).
  • The balance sheet shows a strong capitalization backdrop: total equity around $446.7 million against modest liabilities ($38.1 million total liabilities as of Q3 2025), suggesting a well-capitalized balance sheet relative to near-term obligations.
  • Redeemable noncontrolling interest is present (about $196.5 million as of Q2 2025), reflecting the SPAC structure and potential for changes in ownership arrangements.
  • Equity issuance contributed to dilution: weighted average shares outstanding for Q3 2025 were around 43.5 million (basic/diluted), with ~80.0 million for Q4 2025 on a weighted basis, signaling dilution risk for existing investors.
  • Net income remains negative in 2025, with Q4 2025 net income (continuing operations) at $-91,848,391 and Q3 2025 at $-44,757,000, highlighting ongoing profitability challenges.
  • Operating cash flow is negative in key 2025 quarters: Q3 2025 net cash from continuing operating activities is $-70,626,000, and Q4 2025 is $-42,234,000, signaling sustained cash burn from operations.
  • The third-quarter 2025 period shows a large overall cash decline, with net change in cash & equivalents of about $-378,923,546, underscoring substantial quarterly cash outflows even with financing inflows.
  • Financing activity in Q4 2025 was modestly negative ($-586,000), indicating some retreat in cash-raising activity and continued sensitivity to access to capital markets for runway.
05/14/26 05:07 PM ETAI Generated. May Contain Errors.

BridgeBio Oncology Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, BridgeBio Oncology Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

BridgeBio Oncology Therapeutics' net income appears to be on an upward trend, with a most recent value of -$134.04 million in 2025, rising from -$41.69 thousand in 2023. The previous period was -$74.28 million in 2024. See where experts think BridgeBio Oncology Therapeutics is headed by visiting BridgeBio Oncology Therapeutics' forecast page.

BridgeBio Oncology Therapeutics' total operating income in 2025 was -$145.82 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $145.82 million

Over the last 2 years, BridgeBio Oncology Therapeutics' total revenue changed from $0.00 in 2023 to $0.00 in 2025, a change of 0.0%.

BridgeBio Oncology Therapeutics' total liabilities were at $37.29 million at the end of 2025, a 90.4% increase from 2024, and a 9,304.4% increase since 2023.

In the past 2 years, BridgeBio Oncology Therapeutics' cash and equivalents has ranged from $0.00 in 2023 to $373.69 million in 2025, and is currently $373.69 million as of their latest financial filing in 2025.

Over the last 2 years, BridgeBio Oncology Therapeutics' book value per share changed from 0.00 in 2023 to 5.14 in 2025, a change of -122,466.7%.


Related Companies

Financial statements for NASDAQ:BBOT last updated on 4/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Peptide Company Lands Exclusive MMA Wellness Partnership
A publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...
The Tomorrow Investor | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Distracted Americans set to miss out on quadrillions
Technology expert and Washington D.C. insider Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - s...
Brownstone Research | Sponsoredtc pixel